{"product_id":"bio-techne-five-forces-analysis","title":"Bio-Techne Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBio-Techne faces moderate supplier power and differentiated product strength, while customer concentration and niche competitors shape pricing flexibility; regulatory hurdles and biotech innovation drive both barriers and substitute threats. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Bio-Techne’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Techne depends on high-purity biological reagents, specialized antibodies, and niche chemicals often from few premium vendors; in 2024 ~60% of critical antibodies came from three suppliers, concentrating risk. Switching suppliers triggers validation costs and delays—typical lot qualification takes 6–12 weeks and can cost $50k–$200k per assay—so firms avoid frequent changes. This creates moderate supplier leverage on price and 4–10 week supply timelines, impacting gross margins and R\u0026amp;D schedules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Proprietary Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMany key components for advanced diagnostics and genomic tools are patent-protected by third parties, and Bio-Techne (NASDAQ: TECH) often licenses these to integrate into its platforms, creating supplier power over critical IP.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Bio-Techne reported 2024 revenue of $1.19 billion, and reliance on licensed modules means a modest \u0026gt;5% input cost swing from IP royalties could cut gross margin noticeably.\u003c\/p\u003e\n\u003cp\u003eThis dependency restricts Bio-Techne’s ability to push for lower prices or alternate suppliers, since switching risks license breaches, delayed product launches, and lost market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market for Specialized Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe supply of highly skilled scientists, molecular biologists, and engineers is a bottleneck for Bio‑Techne’s R\u0026amp;D; by 2025 the US biotech sector added ~42,000 STEM jobs year‑over‑year, lifting median biotech salaries ~6–8% and raising Bio‑Techne’s labor costs (2024 R\u0026amp;D expense was $121.7M). These specialists wield strong supplier power since their expertise is essential to sustain product pipelines and switching costs are high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA substantial share of Bio-Techne’s reagents are temperature-sensitive and need certified cold-chain carriers; globally, fewer than 30 providers offer validated -20°C to -80°C international services to emerging hubs as of 2025, creating supplier concentration.\u003c\/p\u003e\n\u003cp\u003eThat concentration lets logistics firms pass higher fuel and infrastructure costs to Bio-Techne—air freight rates rose ~22% in 2022–24 and pharma cold-chain premiums remain 15–30% above standard rates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew than 30 global certified cold-chain providers (-20 to -80°C)\u003c\/li\u003e\n\u003cli\u003eAir freight rates +22% (2022–24)\u003c\/li\u003e\n\u003cli\u003eCold-chain premiums 15–30% above standard\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Concentration of Commodity Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor standard lab consumables and basic reagents, suppliers are highly fragmented—global distributors like VWR\/Avantor and Fisher Scientific share market slices but no single supplier dominates, keeping switch costs low for Bio-Techne.\u003c\/p\u003e\n\u003cp\u003eThis fragmentation lowers supplier bargaining power; Bio-Techne can re-source commodities quickly, protecting margins—procurement flexibility helped contain COGS pressure in 2024 when raw-material volatility rose ~7% YoY.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMany vendors; low concentration\u003c\/li\u003e\n\u003cli\u003eLow switching costs; minimal disruption\u003c\/li\u003e\n\u003cli\u003eProcurement agility reduced supplier leverage\u003c\/li\u003e\n\u003cli\u003eHelped contain COGS amid 7% raw-material volatility in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio‑Techne's supplier squeeze: 60% antibodies from 3 vendors, costly cold‑chain pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Techne faces moderate supplier power: ~60% of critical antibodies sourced from three vendors in 2024, lot qualification 6–12 weeks costing $50k–$200k, and IP royalties that can swing gross margin \u0026gt;5%; fragmented consumables market and procurement agility partly offset leverage. Cold‑chain and skilled STEM labor bottlenecks (2024 R\u0026amp;D $121.7M; US biotech added ~42k STEM jobs by 2025) add cost pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCritical antibodies from 3 suppliers (2024)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLot qualification time\u003c\/td\u003e\n\u003ctd\u003e6–12 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLot qualification cost\u003c\/td\u003e\n\u003ctd\u003e$50k–$200k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio‑Techne revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.19B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D expense (2024)\u003c\/td\u003e\n\u003ctd\u003e$121.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS biotech STEM jobs added (2025)\u003c\/td\u003e\n\u003ctd\u003e~42,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAir freight change (2022–24)\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain premium\u003c\/td\u003e\n\u003ctd\u003e15–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces for Bio-Techne, uncovering competitive intensity, buyer\/supplier power, entry barriers, substitute threats, and strategic levers—highlighting disruptive forces and actionable implications for pricing, margins, and growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces one-sheet tailored to Bio-Techne—instantly pinpoint supplier, buyer, rivalry, entrant, and substitute pressures to streamline strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Academic and Clinical Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe consolidation of hospitals, research universities, and diagnostic labs into large systems raises customer volume power: the top 100 US health systems accounted for ~40% of hospital admissions in 2023, pushing centralized procurement to demand institutional discounts from suppliers like Bio-Techne.\u003c\/p\u003e\n\u003cp\u003eCentralized purchasing offices negotiate bulk pricing and multi-year contracts; Bio-Techne sees margin pressure as single labs lose buying autonomy and system-level tenders favor lower-cost providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBudgetary Constraints and Funding Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Bio-Techne’s customers depend on public grants (NIH funding was $45.5B in FY2024), so political or economic shifts make labs price-sensitive and delay instrument capex; when US federal research funding was flat from 2022–2024, capital orders slowed, reducing Bio-Techne’s instrument revenue growth and giving buyers timing power over ~quarterly demand cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Validated Workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOnce a lab validates a Bio-Techne antibody or reagent in a multi-year study or clinical protocol, switching costs rise sharply—replication, revalidation and training often cost 10–30% of a program’s budget and can delay projects by 6–18 months. Consistency needs for longitudinal data and regulatory re-submission for diagnostics create high stickiness, lowering immediate customer bargaining power. In 2024 Bio-Techne reported ~55% recurring revenue from life‑science reagents, underscoring ecosystem lock-in.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Alternative High-Quality Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBio-Techne’s reputation for high-quality reagents and instruments faces direct competition from Thermo Fisher Scientific and Abcam, which together held roughly 28% and 2% of the global life-science tools market in 2024 respectively, giving customers credible alternatives.\u003c\/p\u003e\n\u003cp\u003eBuyers use competitive quotes from these brands to pressure margins; if Bio-Techne’s prices exceed market average by several percentage points, customers can shift new-project spend to rivals with limited switching costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThermo Fisher 2024 market share ~28%\u003c\/li\u003e\n\u003cli\u003eAbcam 2024 share ~2%\u003c\/li\u003e\n\u003cli\u003eLow switching cost for new projects\u003c\/li\u003e\n\u003cli\u003ePrice deviations create leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Service Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomers in life sciences require deep technical expertise and robust post-sale support to ensure experiments succeed; in 2024, Bio-Techne reported ~25% of revenue from premium services that directly address this need.\u003c\/p\u003e\n\u003cp\u003eBy offering superior technical guidance and custom services, Bio-Techne increases repeat purchases and reduces price-driven churn, shifting bargaining power toward the company.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium services ≈25% revenue (2024)\u003c\/li\u003e\n\u003cli\u003eHigher retention from technical support\u003c\/li\u003e\n\u003cli\u003eServices turn customers into partners, not buyers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Techne: System consolidation and NIH pressure vs. high switching costs, recurring revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomers have strong volume-based leverage via consolidated health systems (top 100 US systems ≈40% hospital admissions in 2023) and grant-driven price sensitivity (NIH $45.5B FY2024), pressuring Bio-Techne margins, though high switching costs for validated reagents (10–30% program cost; 6–18 month delay) and ~55% recurring reagent revenue limit immediate buyer power; premium services (~25% revenue in 2024) push retention up.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-100 US systems share\u003c\/td\u003e\n\u003ctd\u003e~40% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH funding\u003c\/td\u003e\n\u003ctd\u003e$45.5B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring reagent revenue\u003c\/td\u003e\n\u003ctd\u003e~55% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePremium services\u003c\/td\u003e\n\u003ctd\u003e~25% revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost \u0026amp; delay\u003c\/td\u003e\n\u003ctd\u003e10–30% cost; 6–18 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eBio-Techne Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Bio-Techne Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders or mockups. The document displayed is fully formatted and ready for download and use the moment you buy. You're viewing the final, professionally written file; once payment is complete, you'll get instant access to this identical deliverable. No surprises, no additional setup required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746957668729,"sku":"bio-techne-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/bio-techne-five-forces-analysis.png?v=1772193708","url":"https:\/\/growthsharematrix.com\/products\/bio-techne-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}